| Literature DB >> 28222123 |
Özden O Dalgıç1, Osman Y Özaltın2, William A Ciccotelli3,4, Fatih S Erenay1.
Abstract
Individuals are prioritized based on their risk profiles when allocating limited vaccine stocks during an influenza pandemic. Computationally expensive but realistic agent-based simulations and fast but stylized compartmental models are typically used to derive effective vaccine allocation strategies. A detailed comparison of these two approaches, however, is often omitted. We derive age-specific vaccine allocation strategies to mitigate a pandemic influenza outbreak in Seattle by applying derivative-free optimization to an agent-based simulation and also to a compartmental model. We compare the strategies derived by these two approaches under various infection aggressiveness and vaccine coverage scenarios. We observe that both approaches primarily vaccinate school children, however they may allocate the remaining vaccines in different ways. The vaccine allocation strategies derived by using the agent-based simulation are associated with up to 70% decrease in total cost and 34% reduction in the number of infections compared to the strategies derived by using the compartmental model. Nevertheless, the latter approach may still be competitive for very low and/or very high infection aggressiveness. Our results provide insights about potential differences between the vaccine allocation strategies derived by using agent-based simulations and those derived by using compartmental models.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28222123 PMCID: PMC5319753 DOI: 10.1371/journal.pone.0172261
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Transition rates between compartments.
Fig 2Cumulative number of infections in each age group of FluTe and the SEIR model after the calibration process for R0 = 1.2 without vaccination.
(a) Total population. (b) Preschool children (0–4). (c) School children (5–18). (d) Young adults (19–29). (e) Adults (30–64). (f) Seniors (65+).
Input parameters of FluTe and the SEIR model.
| SEIR | FluTe | Source | ||||
| Latent period duration (LPD) | 1.9 days | 1.9 days | [ | |||
| Total disease duration (TDD) | 6 days | 6 days | [ | |||
| Infectious period duration (IPD) | 4.1 days | 4.1 days | TDD−LPD | |||
| Transition rate | ||||||
| Exposed-to-Infectious( | 0.52632 | – | (LPD)−1 | |||
| Exposed-to-Recovered ( | 0.1667 | – | (TDD)−1 | |||
| Infectious-to-Recovered ( | 0.2439 | – | (IPD)−1 | |||
| Likelihood | ||||||
| of showing the symptoms ( | 0.67 | 0.67 | [ | |||
| Transmission rate/probability ( | Initial number of infections ( | |||||
| SEIR | FluTe | SEIR | FluTe | |||
| Basic reproduction number ( | 1.2 | 0.0044 | 0.2057 | 19.48 | 10 | Calibration and [ |
| 1.4 | 0.0053 | 0.2435 | 22.07 | 10 | ||
| 1.6 | 0.0063 | 0.2812 | 7.88 | 10 | ||
| 1.8 | 0.0071 | 0.3190 | 5.01 | 10 | ||
| 2.0 | 0.0077 | 0.3567 | 5.01 | 10 | ||
| 2.2 | 0.0083 | 0.3944 | 5.01 | 10 | ||
| 2.4 | 0.0089 | 0.4322 | 5.01 | 10 | ||
| Age group specific disease parameters | ||||||
| 0–4 | 5–18 | 19–29 | 30–64 | 65+ | ||
| Population size | 36,722 | 124,787 | 71,601 | 265,047 | 65,303 | [ |
| Death rate (unvaccinated- | 0.0049 | 0.002 | 0.0056 | 0.0038 | 0.001 | [ |
| Death rate (vaccinated- | 0.0012 | 0.0005 | 0.0017 | 0.0011 | 0.0004 | [ |
| Vaccine efficacy in | ||||||
| becoming infected | 40% | 40% | 40% | 40% | 24% | [ |
| transmitting the disease | 40% | 40% | 40% | 40% | 24% | [ |
| showing the symptoms | 67% | 67% | 67% | 67% | 40% | [ |
| Performance related parameters | ||||||
| 0–4 | 5–18 | 19–29 | 30–64 | 65+ | ||
| Infection cost (unvaccinated)($) | 275.3 | 275.3 | 328.98 | 328.98 | 492.56 | [ |
| Infection cost (vaccinated)($) | 231.58 | 231.58 | 264.71 | 264.71 | 404.54 | [ |
| Terminal care cost($) | 3,435 | 3,435 | 7,605 | 7,605 | 8,309 | [ |
| Vaccination cost ($) | 37.26 | 37.26 | 37.26 | 37.26 | 37.26 | [ |
| YLL (years) | 79.42 | 70.71 | 57.92 | 36.45 | 13.37 | [ |
‡: Mean of a discrete distribution of 1, 2, or 3 days with probabilities 0.3, 0.5, and 0.2.
†: These numbers are for the unvaccinated individuals. For the vaccinated individuals, they should be multiplied by (1- vaccine efficacy in showing the symptoms).
*: These numbers are for the unvaccinated individuals. For the vaccinated individuals, they should be multiplied by (1- vaccine efficacy in transmitting the disease).
Vaccine allocation strategies obtained by FluTe+MADS and SEIR+MADS under the base-case scenario.
| Performance measure | Vaccination fractions for each age group | |||||
|---|---|---|---|---|---|---|
| 0–4 | 5–18 | 19–29 | 30–64 | 65+ | ||
| TC | SEIR+MADS | - | 87% | - | - | - |
| FluTe+MADS | - | 99% | 34% | - | - | |
| TI | SEIR+MADS | 100% | 100% | 9% | - | - |
| FluTe+MADS | 89% | 100% | 9% | 1% | 1% | |
| TD | SEIR+MADS | 100% | 100% | 9% | - | - |
| FluTe+MADS | 5% | 97% | 50% | 3% | 2% | |
| TY | SEIR+MADS | 100% | 100% | 9% | - | - |
| FluTe+MADS | 21% | 98% | 50% | 1% | - | |
R0 = 1.6, 30% vaccine coverage, no delay in response time. TC: Total cost, TI: Total number of infections, TD: Total number of deaths, TY: Total YLL
Objective values of recommended vaccine allocation strategies.
| Performance measure | Sample mean | Difference | p-value | |
|---|---|---|---|---|
| SEIR+MADS | FluTe+MADS | |||
| TC ($M) | 23.2 | 6.5 | 16.7 | <0.001 |
| TI (infections) | 1,170.3 | 945.2 | 225.1 | 0.117 |
| TD (deaths) | 10.7 | 9.9 | 0.8 | 0.584 |
| TY (life years lost) | 459.8 | 367.5 | 92.3 | 0.094 |
R0 = 1.6, 30% vaccine coverage, no delay in response time. The performance measures are calculated using FluTe with 100 replications.
Fig 3Vaccine allocation strategies derived by FluTe+MADS and SEIR+MADS under all objective functions for various R0 values (30% vaccine coverage, no delay in response time).
(a) SEIR+MADS with the TC objective. (b) FluTe+MADS with the TC objective. (c) SEIR+MADS with the TI objective. (d) FluTe+MADS with the TI objective. (e) SEIR+MADS with the TD objective. (f) FluTe+MADS with the TD objective. (g) SEIR+MADS with the TY objective. (h) FluTe+MADS with the TY objective.
Vaccine allocation strategies for different coverage scenarios.
| FluTe+MADS | SEIR+MADS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine coverage | Vaccination fraction for each age group ( | Vaccination fraction for each age group ( | |||||||||
| 0–4 | 5–18 | 19–29 | 30–64 | 65+ | 0–4 | 5–18 | 19–29 | 30–64 | 65+ | ||
| 20% | 1% | 88% | 1% | - | - | - | 87% | - | - | - | |
| 30% | - | 99% | 34% | - | - | - | 87% | - | - | - | |
| 40% | 34% | 98% | 22% | 2% | 3% | - | 87% | - | - | - | |
| 20% | 2% | 87% | 2% | - | 1% | - | 90% | - | - | - | |
| 30% | 89% | 100% | 9% | 1% | 1% | 100% | 100% | 9% | - | - | |
| 40% | 64% | 98% | 99% | 2% | 1% | 100% | 100% | 84% | - | 3% | |
| 20% | 15% | 80% | - | - | 10% | - | 90% | - | - | - | |
| 30% | 5% | 97% | 50% | 3% | 2% | 100% | 100% | 9% | - | - | |
| 40% | 6% | 100% | 96% | 11% | - | 100% | 100% | 80% | 2% | - | |
| 20% | 34% | 70% | 6% | - | 12% | - | 90% | - | - | - | |
| 30% | 21% | 98% | 50% | 1% | - | 100% | 100% | 9% | - | - | |
| 40% | 64% | 98% | 98% | 2% | 2% | 84% | 100% | 95% | - | - | |
R0 = 1.6, no response delay
Vaccine allocation strategies for different response time scenarios.
| SEIR+MADS | FluTe+MADS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Response time (days) | Vaccination fraction for each age group ( | Vaccination fraction for each age group ( | |||||||||
| 0–4 | 5–18 | 19–29 | 30–64 | 65+ | 0–4 | 5–18 | 19–29 | 30–64 | 65+ | ||
| P | – | 86% | – | – | – | 19% | 100% | – | – | 4% | |
| 0 | – | 87% | – | – | – | – | 99% | 34% | – | – | |
| 10 | – | 89% | – | – | – | 77% | 100% | 15% | – | 5% | |
| 20 | – | 91% | – | – | – | 46% | 100% | 31% | – | 4% | |
| 40 | – | 96% | – | – | – | – | 96% | 49% | 5% | – | |
| 60 | – | 100% | – | – | – | 23% | 83% | 71% | – | 8% | |
| 80 | 1% | 100% | – | – | – | 48% | 6% | – | 54% | – | |
| 90 | 72% | 100% | – | – | – | 4% | 5% | – | 55% | – | |
| P | 100% | 100% | 1% | – | 9% | 16% | 100% | 43% | – | – | |
| 0 | 100% | 100% | 9% | – | – | 89% | 100% | 9% | 1% | 1% | |
| 10 | 100% | 100% | 9% | – | – | 67% | 99% | 16% | 2% | 2% | |
| 20 | 100% | 100% | 7% | 1% | – | – | 100% | 39% | 5% | – | |
| 40 | 100% | 100% | 9% | – | – | 19% | 100% | – | 14% | – | |
| 60 | 100% | 100% | 9% | – | – | 30% | 93% | 52% | – | 5% | |
| 80 | 100% | 100% | 1% | 2% | – | 56% | 65% | 88% | – | 4% | |
| 90 | 100% | 100% | 1% | 2% | – | 59% | 40% | – | 36% | – | |
| P | 100% | 100% | 9% | – | – | 13% | 100% | 17% | 9% | 1% | |
| 0 | 100% | 100% | 9% | – | – | 5% | 97% | 50% | 3% | 2% | |
| 10 | 100% | 100% | 9% | – | – | – | 100% | 60% | – | – | |
| 20 | 100% | 100% | 9% | – | – | 14% | 100% | 27% | 6% | 6% | |
| 40 | 100% | 100% | 9% | – | – | – | 100% | 60% | – | – | |
| 60 | 100% | 100% | 5% | 1% | – | 66% | 98% | 23% | – | 8% | |
| 80 | 100% | 100% | 9% | – | – | 100% | – | 100% | 22% | – | |
| 90 | 100% | 100% | 9% | – | – | 87% | – | 100% | 24% | – | |
| P | 100% | 100% | 9% | – | – | 71% | 100% | 10% | 2% | 6% | |
| 0 | 100% | 100% | 9% | – | – | 21% | 98% | 50% | 1% | – | |
| 10 | 100% | 100% | 9% | – | – | 93% | 98% | – | 4% | – | |
| 20 | 100% | 100% | 9% | – | – | 36% | 100% | 37% | – | 4% | |
| 40 | 100% | 100% | 9% | – | – | 1% | 100% | 59% | – | – | |
| 60 | 100% | 100% | 9% | – | – | 100% | 100% | 9% | – | 1% | |
| 80 | 100% | 100% | 9% | – | – | 100% | 47% | 100% | – | – | |
| 90 | 100% | 100% | 9% | – | – | 100% | 100% | – | 2% | – | |
R0 = 1.6, 30% vaccine coverage. P: Prevaccination.